Advocacy intelligence hub — real-time data for patient organizations
Merck Sharp & Dohme LLC — PHASE2
Taiho Oncology, Inc. — PHASE2
Regor Pharmaceuticals Inc. — PHASE1
Novartis Pharmaceuticals — PHASE4
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Boon Cher Goh
National University of Singapore
Jian Zhang, MD
Fudan University
Daniel SW Tan
National Cancer Centre, Singapore
BioNTech Responsible Person
BioNTech SE
Jared Weiss, MD
UNC at Chapel Hill
Yuankai Shi, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences